Skip to main content

Novel approaches to support therapeutic development in ultra-rare cancers

Agency: Food and Drug Administration

Assistance Listings
  • 93.103 -- Food and Drug Administration Research

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: Not specified
  • Forecasted application due date: Not specified
  • Forecasted award date: Not specified
  • Forecasted project start date: Not specified
  • Fiscal Year: 2026

Award details

  • Expected project funding: Not specified
  • Expected awards: 2

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:FOR-FD-26-004
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Agriculture
    • Consumer protection
    • Food and nutrition
  • Category Explanation:Not specified

History

  • Forecast posted date: August 4, 2025
  • Archive date: Not specified
  • Version: 2

View version history on Grants.gov

Summary

The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. 


Specific areas of interest include, but are not limited to, the following examples:

• Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers.

• Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers.

• Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG). 

• Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs), including drugs for which development has been discontinued, in ultra-rare cancers.

• Research to develop novel approaches to preserve the availability of drugs for which commercial developers have discontinued adult development that have strong potential in ultra-rare cancers but lack financial incentives for commercial development

• Development of methods to incorporate use of telemedicine and/or pragmatic trial design elements (e.g., collecting laboratory and/or imaging data from local facilities) for patient assessments to facilitate enrollment of patients with ultra-rare cancers

• Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors in metastatic tumor animal models using targeted bioPROTAC degradation or genomic editing strategies. Successful efforts should demonstrate effective delivery and expression in-vivo to tumor cells, and downregulation of the target transcription factor protein while minimizing off-target effects and limiting sequestration of the nanoparticle by the liver, spleen, and lungs.

• Research to exhaustively characterize the plasma-membrane protein expression (surfaceome) of an ultra-rare cancer and the presumed healthy tissue of origin, as well as the resident-tissue stem cells, by single-cell transcriptomics and proteomics. These studies, and available correlative database analyses, should be designed to identify possible combinatorial signatures of plasma membrane proteins unique to the ultra-rare tumor. Tumors of interest include Sclerosing epithelioid fibrosarcoma and atypical teratoid rhabdoid tumors (ATRT).


Eligibility

Education

  • Independent school districts
  • Public and state institutions of higher education
  • Private institutions of higher education

Government

  • State governments
  • Federally recognized Native American tribal governments
  • County governments
  • Public and Indian housing authorities
  • Special district governments
  • City or township governments

Nonprofit

  • Nonprofits non-higher education without 501(c)(3)
  • Other Native American tribal organizations
  • Nonprofits non-higher education with 501(c)(3)

Business

  • For-profit organizations other than small businesses
  • Small businesses

Additional information on eligibility

Not specified

Documents

No documents are currently available.

Agency contact information

Email: patrick.johnson@fda.hhs.gov

Contact FDA About this Opportunity

Patrick Johnson Grants Management Specialist 301-796-0154

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov